

# Prostate Cancer - Pipeline Review, H1 2020

<https://marketpublishers.com/r/PA6A3B09973EN.html>

Date: May 2020

Pages: 2967

Price: US\$ 2,500.00 (Single User License)

ID: PA6A3B09973EN

## Abstracts

Prostate Cancer - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer – Pipeline Review, H1 2020, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 19, 169, 130, 1, 15, 264, 49 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 12, 17, 1, 69 and 26 molecules, respectively.

Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Prostate Cancer - Overview

Prostate Cancer - Therapeutics Development

Prostate Cancer - Therapeutics Assessment

Prostate Cancer - Companies Involved in Therapeutics Development

Prostate Cancer - Drug Profiles

Prostate Cancer - Dormant Projects

Prostate Cancer - Discontinued Products

Prostate Cancer - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Prostate Cancer, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020  
Prostate Cancer - Pipeline by 4D Pharma Plc, H1 2020  
Prostate Cancer - Pipeline by 4SC AG, H1 2020  
Prostate Cancer - Pipeline by AB Science SA, H1 2020  
Prostate Cancer - Pipeline by Abbisko Therapeutics Co Ltd, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Prostate Cancer, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

4D Pharma Plc  
4SC AG  
AB Science SA  
Abbisko Therapeutics Co Ltd  
AbbVie Inc  
Abion Inc  
Actinium Pharmaceuticals Inc  
ADC Therapeutics SA  
Adicet Bio Inc  
Aduro BioTech Inc  
Advanced Accelerator Applications SA  
Advanced Cancer Therapeutics LLC  
Advaxis Inc  
Adze Biotechnology Inc  
Aeglea BioTherapeutics Inc  
Affina Biotechnologies Inc  
Agenus Inc  
AIM ImmunoTech Inc  
Akshaya Bio Inc  
Alla Chem LLC  
Allife Medical Science and Technology Co Ltd

Alligator Bioscience AB  
Almac Discovery Ltd  
AlphaMab Co Ltd  
Alphamab Oncology  
ALRISE Biosystems GmbH  
Altay Therapeutics Inc  
Altum Pharmaceuticals Inc  
Ambrx Inc  
American Gene Technologies International Inc  
Amgen Inc  
Anastasis Biotec Ltd  
Anavex Life Sciences Corp  
Andes Biotechnologies  
Anew Oncology Inc  
AnGes Inc  
AntiCancer Inc  
Antikor Biopharma Ltd  
Apcure SAS  
Apexian Pharmaceuticals Inc  
Aphios Corp  
Apidel SA  
APIM Therapeutics AS  
Aqualung Therapeutics Corp  
Aranda Pharma Ltd  
Arcus Biosciences Inc  
Arrien Pharmaceuticals LLC  
Artelo Biosciences Inc  
Arvinas Inc  
Ascelia Pharma AB  
Asdera LLC  
Asieris Pharmaceuticals Co Ltd  
AskAt Inc  
AstraZeneca Plc  
Athenex Inc  
AUM Biosciences Pte Ltd  
Auransa Inc  
Aurigene Discovery Technologies Ltd  
Autolus Therapeutics Plc  
Avican Inc

Avivia BV  
B3 Bio Inc  
Bantam Pharmaceutical LLC  
Basilea Pharmaceutica Ltd  
Bavarian Nordic A/S  
Bayer AG  
BeiGene Ltd  
Bellicum Pharmaceuticals Inc  
Bexion Pharmaceuticals LLC  
BeyondSpring Inc  
Bio-Cancer Treatment International Ltd  
BioAtla LLC  
BioCurity Pharmaceuticals Inc  
BioEclipse Therapeutics Inc  
Biokine Therapeutics Ltd  
BioNTech SE  
Biopep Solutions Inc  
Biosceptre International Ltd  
Biosion Inc  
BioVec Pharma Inc  
Bioven Group  
BioXcel Therapeutics Inc  
bluebird bio Inc  
Boehringer Ingelheim International GmbH  
BriaCell Therapeutics Corp  
Bristol-Myers Squibb Co  
Bukwang Pharm Co Ltd  
Calidi Biotherapeutics Inc  
Calidum Inc  
Camurus AB  
Can-Fite BioPharma Ltd  
CanBas Co Ltd  
Cancer Targeted Technology LLC  
Candel Therapeutics  
Canget BioTekpharma LLC  
Cantex Pharmaceuticals Inc  
Cardiff Oncology Inc  
Carrick Therapeutics UK Ltd  
CAS-Lamvac Biotech Co Ltd



Cassiopea SpA  
Cellbion Co Ltd  
CellCentric Ltd  
Celldex Therapeutics Inc  
Cellestia Biotech AG  
Cellid Co Ltd  
Cellmid Ltd  
Cello Therapeutics Inc  
Cells for Cells SA  
Cellular Biomedicine Group Inc  
Celprogen Inc  
Celtek Bioscience LLC  
CG Oncology Inc  
ChemRegen Inc  
Chong Kun Dang Pharmaceutical Corp  
Clarity Pharmaceuticals Pty Ltd  
Cloaked Therapeutics LLC  
Clovis Oncology Inc  
CMG Pharmaceutical Co Ltd  
Codagenix Inc  
CohBar Inc  
Constellation Pharmaceuticals Inc  
Context Therapeutics LLC  
Convalife  
Corcept Therapeutics Inc  
Corvus Pharmaceuticals Inc  
Crescendo Biologics Ltd  
Cue Biopharma Inc  
Curadis GmbH  
CureLab Oncology Inc  
CureMeta LLC  
Cytodyn Inc  
CytoMed Therapeutics Pte Ltd  
CytomX Therapeutics Inc  
CytoVac AS  
CZ BioMed Corp  
Daewon Pharmaceutical Co Ltd  
Daewoong Pharmaceutical Co Ltd  
Daiichi Sankyo Co Ltd

Debiopharm International SA  
Deciphera Pharmaceuticals Inc  
DEKK-TEC Inc  
DevaCell Inc  
DexTech Medical AB  
Diakonos Research Ltd  
Diffusion Pharmaceuticals Inc  
DisperSol Technologies LLC  
Disulfican Ltd  
DNJ Pharma Inc  
Druggability Technologies Holdings Ltd  
eFFECTOR Therapeutics Inc  
Eli Lilly and Co  
Ellipses Pharma Ltd  
Emtora Biosciences  
Enceladus Pharmaceuticals BV  
EndoCeutics Inc  
Endocyte Inc  
EntreChem SL  
EOS Biosciences Inc  
Epigene Therapeutics Inc  
Epizyme Inc  
Errant Gene Therapeutics LLC  
Ervaxx Ltd  
Esanex Inc  
Esperance Pharmaceuticals Inc  
ESSA Pharma Inc  
EstryX Pharma Ltd  
Etubics Corp  
Eurofarma Laboratorios SA  
Evgen Pharma Plc  
Exelixis Inc  
F. Hoffmann-La Roche Ltd  
FeliciteX Therapeutics Inc  
Ferring International Center SA  
For-Robin Inc  
Foresee Pharmaceuticals Co Ltd  
Forma Therapeutics Inc  
Fortis Therapeutics Inc

Fujifilm Holdings Corp  
Fusion Antibodies Plc  
G1 Therapeutics Inc  
Galectin Therapeutics Inc  
GEMoAB Monoclonals GmbH  
GemVax & KAEL Co Ltd  
Gene Sciences Inc  
Genelux Corp  
Genentech Inc  
Geneos Therapeutics Inc  
GeneScience Pharmaceuticals Co Ltd  
Genetic Immunity Inc  
GenKyoTex SA  
Genmab AS  
GeoVax Labs Inc  
Gibson Oncology LLC  
Gilead Sciences Inc  
Glactone Pharma AB  
GlaxoSmithKline Plc  
GLG Pharma SA  
Glycomantra Inc  
GlycoMimetics Inc  
GlycoNex Inc  
GlyTech Inc  
GlyTherix Ltd  
Gossamer Bio Inc  
GP Pharm SA  
Guangzhou Anjie Biomedical Technology Co Ltd  
Hanmi Pharmaceuticals Co Ltd  
Harbin Gloria Pharmaceuticals Co Ltd  
Harpoon Therapeutics Inc  
Health Ever Bio-Tech Co Ltd  
Heidelberg Pharma AG  
Helixmith Co Ltd

## I would like to order

Product name: Prostate Cancer - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/PA6A3B09973EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PA6A3B09973EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970